Exo Biologics

Romain de Rauville, M.D., Chief Business Officer

April 11 | 10:15am | Salone dei Cavalieri, Section 2

Liege, Belgium


EXO Biologics is a Belgian biotech company committed to developing biopharmaceuticals using Extra Vesicles/Exosomes to treat rare diseases with unmet medical needs. In 2023, EXO Biologics received the authorization by EMA to start EVENEW: its clinical phase I trial for BPD (Broncho Pulmonary Dysplasia). EXO Biologics hence became the first company in the world to ever obtain an MSC-derived Extracellular Vesicles interventional study approved by the European Medicines Agency. EXO Biologics is now a world leader within the exosomes space as it successfully resolved the process development and regulatory challenges for starting clinical trials. The company is therefore now paving the way for the young but promising exosome field not only as a therapeutic but also as delivery vehicle.


By using this website you agree to accept our Privacy Policy and Terms & Conditions